About ANTEGREN Natalizumab, a humanized monoclonal antibody, is the first alpha-4 antagonist in the new selective adhesion molecule inhibitor. The drug is to preventing the migration of immune cells into chronically inflamed may cause may cause or maintain inflammation.

The ENACT-1 trial was a 3 – month Phase III trial of natalizumab in Crohn’s disease induction. It did not meet its primary endpoint, but a significant proportion of patients with active inflammation had statistically significant clinical response and remission rates at week 10 and several other points in time in comparison to placebo.* In the U.S., Avastin for use in combination with intravenous 5 – fluorouracil-based chemotherapy for first-line treatment for patients with metastatic the colon or rectum approved.

Other articles from category "phlebology":

Random articles